Purchase this article with an account.
Frank D Verbraak, Jurre den Haan, Aleid van de Kreeke, Frederik Barkhof, Bart N van Berckel, Charlotte E Teunissen, Philip Scheltens, Pieter Jelle Visser, Femke H Bouwman; Retinal thickness as biomarker in patients with amyloid proven Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1271. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Retinal thickness measured with optical coherence tomography (OCT) is hypothesized to be a non-invasive biomarker for Alzheimer’s disease (AD), but is also influenced by age-related ophthalmological disease. We therefore measured retinal thickness in well-characterized AD and control participants.
We included 57 AD cases with evidence of amyloid pathology, and 85 cognitively normal, amyloid negative controls. All subjects underwent a thorough ophthalmological assessment to exclude ocular disease, and included retinal thickness measurements with OCT.
Retinal thickness did not discriminate cases from controls, also stratified for early versus late onset AD. We found significant associations between macular thickness and Global Cortical Atrophy (Beta -0.314;p=0.001) and Parietal Cortical Atrophy (Beta -0.276;p=0.003).
In this study, representing the largest OCT study of amyloid proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuro-imaging and CSF measures, querying the use of retinal thickness measurements as AD biomarker.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only